Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deficient endogenous enzymes in inherited metabolic disorders are a class of therapeutic targets characterized by the absence or malfunction of specific enzymes due to genetic mutations. These deficiencies disrupt normal metabolic pathways, leading to the accumulation of toxic substrates or deficiency of essential products. Therapeutic strategies aim to restore enzyme function or mitigate the consequences of enzyme deficiency through enzyme replacement, substrate reduction, or gene therapy.
Enzyme replacement, substrate reduction, gene therapy
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deficient Endogenous Enzymes in Inherited Metabolic Disorders.